Skip to main content

Table 1 Basic clinical characteristics of patients in the TCGA cohort and CPTAC Cohort

From: A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma

  TCGA Cohort (531) CPTAC Cohort (98)
Age(years)
 ≥65 198(37.3%) 41(41.8%)
 <65 333(62.7%) 57(58.2%)
Sex
 Male 345(65.0%) 75(76.5%)
 Female 186(35.0%) 23(23.5%)
Grade
 G1 13(2.4%) 6(6.1%)
 G2 229(43.1%) 47(48.0%)
 G3 205(38.6%) 36(36.7%)
 G4 76(14.3%) 9(9.2%)
 Unknown 8(1.5%) 0
Stage
 I 266(50.1%) 46(46.9%)
 II 57(10.7%) 11(11.2%)
 III 124(23.4%) 31(31.6%)
 IV 84(15.8%) 10(10.2%)
T stage
 T1 271(51.0%) 48(49.0%)
 T2 69(13.0%) 12(12.2%)
 T3 180(33.9%) 37(37.8%)
 T4 11(2.1%) 1(1.0%)
N stage
 N1 16(3.0%) /
 N0 240(45.2%) /
 Unknown 275(51.8%) /
M stage
 M1 79(14.9%) /
 M0 422(79.5%) /
 Unknown 30(5.6%) /
Survival
 Dead 175(33.0%) 12(12.2%)
 Living 356(67.0%) 86(87.8%)